5 Revealing Analyst Questions From Acadia Healthcare’s Q1 Earnings Call

Acadia Healthcare’s first quarter results were met with a significant negative market reaction, despite revenue growth exceeding analyst expectations. Management emphasized that the acute inpatient psychiatric business was the primary driver of performance, with increased patient volumes and strong demand for behavioral health services. CEO Debra Osteen also highlighted operational improvements and cost efficiencies, particularly in newly opened facilities, as key contributors to outperformance. However, certain segments—such as specialty facilities in Pennsylvania—continued to face challenges, while weather disruptions affected growth in the company’s CTC (Comprehensive Treatment Center) segment. The quarter also saw leadership changes at multiple levels, reflecting a renewed focus on operational discipline.

Is now the time to buy ACHC? Find out in our full research report (it’s free for active Edge members).

While we enjoy listening to the management's commentary, our favorite part of earnings calls are the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention.

Our Top 5 Analyst Questions From Acadia Healthcare’s Q1 Earnings Call

• Benjamin Mayo (Leerink Partners): Asked for specifics on correction plans for underperforming new facilities. CEO Debra Osteen emphasized tailored action plans by facility and market, with a focus on expanding access, aligning with partners, and improving service lines.
• Benjamin Mayo (Leerink Partners): Inquired about increased payer denials and bad debts. CFO Todd Young explained denials remain broad-based, with ongoing efforts in documentation and appeals. Osteen added the company is bringing in external expertise to further improve collections.
• Matthew Gillmor (KeyBanc): Questioned the seasonality in EBITDA guidance and the contribution from Medicaid supplementals and ramping facilities. Young noted that ramping facilities and slightly higher supplementals are the main drivers, with back-half improvement expected.
• Pito Chickering (Deutsche Bank): Asked if payers are pushing back on length of stay and how that impacts admissions. Young clarified that changes in patient mix, with more acute beds and fewer specialty beds, drive lower average length of stay but higher admissions.
• Brian Tanquilut (Jefferies): Sought details on corporate overhead reduction and operational structure. Osteen described streamlined middle management and reduced divisional geography to improve decision-making and oversight, especially for JV facilities.

Catalysts in Upcoming Quarters

Going forward, our analyst team will focus on (1) progress in raising occupancy and profitability at recently opened and underperforming facilities, (2) stabilization or improvement in payer denial and bad debt rates following documentation and process enhancements, and (3) the impact of new leadership structure on operational efficiency and JV performance. We will also track how well volume growth balances against ongoing specialty segment headwinds.

Acadia Healthcare currently trades at $25.25, down from $28.26 just before the earnings. Is there an opportunity in the stock?The answer lies in our full research report (it’s free).

Our Favorite Stocks Right Now

ONE MORE THING: Top 5 Growth Stocks. The biggest stock winners almost always had one thing in common before they ran. Revenue growing like crazy. Meta. CrowdStrike. Broadcom. Our AI flagged all three. They returned 315%, 314%, and 455%, respectively.

Find out which 5 stocks it's flagging for this month - FREE. Get Our Top 5 Growth Stocks for Free HERE.

Stocks that have made our list include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,754% five-year return). Find your next big winner with StockStory today.